Life Sciences Legislation And Regulation To Watch In 2017

Law360, New York (January 2, 2017, 1:03 PM EST) -- The impending administration change has life sciences experts wondering what sort of regulatory environment to expect in 2017, and amid the uncertainty, they'll be closely watching the implementation of the 21st Century Cures Act and looking for possible U.S. Food and Drug Administration guidance on interchangeable biologics and off-label promotion.

Of course, with regulations somewhat dependent on whom President-elect Donald Trump names to head the FDA, his choice will set the agency's tone, experts say.

"This could be a very interesting year in the sense that people don't really know what's coming up," said Albert F. Cacozza Jr., a partner at...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!